Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit-Reference-Cited by-同舟云学术

Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit

Published:2021-12 Issue: Volume: Page:
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Desai Nihar,Xie Jipan,Wang Yan,Sutton Megan B.,Whang John,Fine Jennifer T.,Garrison Louis P.^ORCID

Funder

MyoKardia

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference52 articles.

1. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy;Toepfer;Circulation,2020

2. Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light;Trivedi;Biophys Rev,2018

3. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC);Elliott;Eur Heart J,2014

4. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;J Am Coll Cardiol,2020

5. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy;Elliott;Heart,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy;Clinical Therapeutics;2024-04

2. Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review;Heart, Lung and Circulation;2023-09

3. New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy;Cardiovascular & Hematological Agents in Medicinal Chemistry;2023-07

4. Mavacamten in obstructive hypertrophic cardiomyopathy: a profile of its use;Drugs & Therapy Perspectives;2023-06-22

5. Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management;Annals of Pharmacotherapy;2023-06-16